| Literature DB >> 32594100 |
Ying Wang1,2,3, Yang Liu1,2,3, Xu Tan4, Bin Pan1,2,3, Jian Ge5, Kunming Qi1,2,3, Hai Cheng1,2,3, Jiang Cao1,2,3, Ming Shi6,7, Zhiling Yan1,2,3, Jianlin Qiao1,2,3, Guangjun Jing8, Xue Wang1,2,3, Wei Sang1,2,3, Ruixiang Xia5, Xi Zhang4, Zhenyu Li1,2,3, Robert Peter Gale9, Junnian Zheng10,11, Feng Zhu12,13,14, Kailin Xu15,16,17.
Abstract
Chimeric antigen receptor (CAR)-T-cell is a safe and effective therapy of B-cell cancers but it is unknown if this is so in persons with prior hepatitis B virus (HBV) infection. We studied 70 subjects with advanced B-cell cancers receiving CAR-T-cell therapy, 12 of whom had chronic HBV-infection (HBsAg positive) and 29 with resolved HBV-infection (HBsAg negative and anti-HBc positive). Safety and efficacy were compared with 29 subjects without HBV-infection. HBV was reactivated in 2 subjects with chronic HBV-infection and 1 with resolved HBV-infection. There was no HBV-related hepatitis flare. Responses to CAR-T-cell therapy in the three cohorts were not significantly different. There was no significant difference in the incidence or severity of cytokine release syndrome (CRS) and neurologic toxicity between the cohorts. Our data suggest that chronic and resolved HBV-infection do not affect the safety and efficacy of CAR-T-cell therapy.Entities:
Mesh：
Substances：
Year: 2020 PMID： 32594100 DOI： 10.1038/s41375-020-0936-4
Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528